Cormorant Asset Management AVBP Position
ExitedCormorant Asset Management exited their position in ArriVent BioPharma, Inc. (AVBP) in Q1 2025, after holding the stock for 5 quarters.
The position was first reported in Q1 2024 and has been tracked across 5 quarterly 13F filings.
2 other tracked funds also hold AVBP.
There is an upcoming Phase 3 readout for Firmonertinib in 929 days (Oct 31, 2028), making the timing of Cormorant's position particularly relevant.
Short interest stands at 21.3% of float with 13.2 days to cover, indicating significant bearish positioning against the stock.
About ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Full company profile →Short Interest
21.3%
13.2 days to cover
Cormorant Asset Management AVBP Position History
Frequently Asked Questions
Does Cormorant Asset Management own AVBP?
No. Cormorant Asset Management exited their position in ArriVent BioPharma, Inc. (AVBP) in Q1 2025. They previously held the stock for 5 quarters.
How many hedge funds own AVBP?
2 specialist biotech hedge funds currently hold AVBP, including OrbiMed Advisors, Perceptive Advisors. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Cormorant Asset Management first buy AVBP?
Cormorant Asset Management's position in AVBP was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Cormorant Asset Management's AVBP position increasing or decreasing?
Cormorant Asset Management completely exited their AVBP position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
AVBPCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Cormorant Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →